title: A Novel Analytical Method of Cisplatin Using the HPLC with a Naphthylethyl Group Bonded with Silica Gel (πNAP) Column.
abstract: Cisplatin is the most widely used anticancer drug in the world. Mono-chloro and none-chloro complexes of cisplatin may be believed to be the activated compounds. The separation of these compounds using octa decyl silyl column or aminopropylsilyl silica gel column is difficult because of high-reactivity and structural similarity. In this study, cisplatin, hydroxo complexes, and OH-dimer were determined by HPLC using a naphthylethyl group bonded with silica gel (πNAP) column. The analytical conditions of HPLC were as follows: analytical column, πNAP column; wave length, 225 nm; column temperature, 40°C; mobile phase, 0.1 M sodium perchlorate, acetonitrile, and perchloric acid (290 : 10 : 3), flow rate, 1.0 mL/min. Sample (20 µL) was injected onto the HPLC system. Retention time of cisplatin, mono-chloride, OH-dimer, and none-chloride was 3.2, 3.4, 3.6, and, 4.3-6.6 min, respectively. Measurable ranges with this method were 1×10-5to 4×10-3M for cisplatin. Correlation coefficient of the calibration curves of cisplatin was 0.999 (p<0.01). The within- and between-day variations of coefficient of variation (CV) were 5% or lower. In this study, injectable formulations in physiological saline solution, water for injection, 5% glucose solution, and 7% sodium bicarbonate precisely were measured the stability and compositional changes upon mixing by πNAP column rather than C18 column. We successfully determined cisplatin, hydroxo complexes, and OH-dimer by HPLC using a πNAP column. Thus the measurement of cisplatin (cis-diamminedichloro-platinum(II), cis-[PtCl2(NH3)2]) (CDDP) should be done using a πNAP column rather than a C18 column or aminopropylsilyl silica gel column.
authors.affiliation: Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences.
authors.forename: Ryuji
authors.initials: R
authors.lastname: Kato
authors.forename: Takaji
authors.initials: T
authors.lastname: Sato
authors.forename: Michiko
authors.initials: M
authors.lastname: Kanamori
authors.forename: Mizuho
authors.initials: M
authors.lastname: Miyake
authors.forename: Ayumi
authors.initials: A
authors.lastname: Fujimoto
authors.forename: Kyohei
authors.initials: K
authors.lastname: Ogawa
authors.forename: Daiki
authors.initials: D
authors.lastname: Kobata
authors.forename: Tomoya
authors.initials: T
authors.lastname: Fujikawa
authors.forename: Yukari
authors.initials: Y
authors.lastname: Wada
authors.forename: Rintaro
authors.initials: R
authors.lastname: Mitsuishi
authors.forename: Kodai
authors.initials: K
authors.lastname: Takahashi
authors.forename: Hideki
authors.initials: H
authors.lastname: Imano
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Ijiri
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Mino
authors.forename: Masahiko
authors.initials: M
authors.lastname: Chikuma
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Tanaka
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Hayashi
mesh_terms: D000970:Antineoplastic Agents / Q000032:analysis; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D002945:Cisplatin / Q000031:analogs & derivatives / Q000032:analysis* / Q000737:chemistry; D007202:Indicators and Reagents; D015394:Molecular Structure; D058428:Silica Gel; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D007202:Indicators and Reagents; D058428:Silica Gel; D002945:Cisplatin